Matinas BioPharma
MTNB
39 hedge funds and large institutions have $3.66M invested in Matinas BioPharma in 2018 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 7 increasing their positions, 14 reducing their positions, and 19 closing their positions.
0.06% less ownership
Funds ownership: 0.24% → 0.18% (-0.06%)
13% less funds holding
Funds holding: 45 → 39 (-6)
32% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 19
50% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 14
58% less capital invested
Capital invested by funds: $8.74M → $3.66M (-$5.08M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$272K |
| 2 |
ECM
Element Capital Management
New York
|
+$227K |
| 3 |
PP
Paloma Partners
Greenwich,
Connecticut
|
+$173K |
| 4 |
IA
IFP Advisors
Tampa,
Florida
|
+$173K |
| 5 |
BCM
BlueCrest Capital Management
St Helier,
Jersey
|
+$143K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$1.39M |
| 2 |
State Street
Boston,
Massachusetts
|
-$471K |
| 3 |
AWMG
Alliance Wealth Management Group
Flemington,
New Jersey
|
-$307K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$290K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$145K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$14K | -369 | Closed |
|
|
PAG
52
Private Advisor Group
Morristown,
New Jersey
| – | -$13K | -350 | Closed |
|
53
AllianceBernstein
Nashville,
Tennessee
| – | -$11K | -284 | Closed |
|
54
Citigroup
New York
| – | -$8.09K | -280 | -99% |
|
55
Legal & General Group
London,
United Kingdom
| – | -$11K | -276 | Closed |
|
56
Barclays
London,
United Kingdom
| – | -$7.28K | -252 | -93% |
|
57
Principal Financial Group
Des Moines,
Iowa
| – | -$8K | -202 | Closed |
|
|
AIP
58
Ameritas Investment Partners
Lincoln,
Nebraska
| – | -$4K | -93 | Closed |
|
MTNB Hedge Fund Activity: Q2 2018 in Review
39 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q2 2018, worth a combined $3.66M — down 58% from $8.74M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of MTNB and 13 opened new positions — a net loss of 6 holders — while 14 trimmed existing stakes and 7 added.
The largest buyer was Goldman Sachs, adding an estimated $272K. The largest seller was BlackRock, cutting an estimated $1.39M.
- 39 institutional investors held Matinas BioPharma (MTNB) as of Q2 2018, down from 45 in Q1 2018.
- Funds reported $3.66M of Matinas BioPharma stock for Q2 2018, down 58% quarter-over-quarter.
- 13 funds opened new Matinas BioPharma positions in Q2 2018 and 19 closed out, a net change of -6 holders.
- The largest Matinas BioPharma buyer in Q2 2018 was Goldman Sachs, an estimated $272K added.
- The largest Matinas BioPharma seller in Q2 2018 was BlackRock, an estimated $1.39M sold.
Based on aggregated 13F filings for Q2 2018.